MedPath

Effectiveness and cost-effectiveness of Korean medicine and Western medicine collaborative treatment for MCI & Dementia- a prospective observational study

Not Applicable
Recruiting
Conditions
Mental and behavioral disorders
Registration Number
KCT0002868
Lead Sponsor
Wonkwang University Sanbon Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
180
Inclusion Criteria

1. adult-patients whose main diagnosis is MCI or dementia (ICD-10 F00, F01, F02, F03, F067, G30 or G31) equal to or below 85 years old among outpatients of participating institutions in the 'second stage pilot project of KM-WM collaborative treatment'.
2. patiens whose global CDR score ranges 0.5 to 2.0 ( 0.5=CDR=2.0)
3. patients who decide to participat in the study by their (or legal representative when the patient has limited ability to agree, but still can express willingness to participate) voluntary will and submit a written consent

Exclusion Criteria

1. those who are currently participating other clinical trial
2. thos who have difficulties in participating in the study as judged by researchers such as
- those who are expected to have difficulty in complying the study schedule
- those who are expected to have difficulty understanding and responding to study questionnaires such as illiteracy, mental and physical weakness

Study & Design

Study Type
Observational Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Seoul-Instrumental activity of daily living (S-IADL);Montreal cognitive assessment (MoCA);Neuropsychiatric Inventory-Questionnaire (NPI-Q);EuroQoL-5 Dimension (EQ-5D);EuroQol-Visual analogue scale (EQ-VAS);Short-form of Geriatric DEpression Scale (S-GDpS);Mini-Mental State Exam (MMSE);Barthel-activity of daily living (Barthel-ADL);Clinical Dementia Rating (CDR);Global Deterioration Scale (GDS);Use of long-tern care service
Secondary Outcome Measures
NameTimeMethod
cost per quality-adjusted life-year (cost per QALY);Incremental Cost-Effectiveness Ratio(ICER);Incremental Net Benefit;Cost-Effectiveness Acceptability Curve;Korean medical pattern identification for dementia
© Copyright 2025. All Rights Reserved by MedPath